VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited
12 août 2021 07h00 HE
|
VYNE Therapeutics Inc.
VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high...
VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone
02 août 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its products AMZEEQ® (minocycline) topical foam, 4%, and...
VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021
27 juil. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter...
VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
19 juil. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or...
VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event
29 juin 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate...
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
06 mai 2021 07h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and...
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
28 avr. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter...
VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
04 mars 2021 16h01 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and...
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
04 mars 2021 07h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December...
VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
01 mars 2021 16h01 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and...